JPH0374677B2 - - Google Patents

Info

Publication number
JPH0374677B2
JPH0374677B2 JP59264579A JP26457984A JPH0374677B2 JP H0374677 B2 JPH0374677 B2 JP H0374677B2 JP 59264579 A JP59264579 A JP 59264579A JP 26457984 A JP26457984 A JP 26457984A JP H0374677 B2 JPH0374677 B2 JP H0374677B2
Authority
JP
Japan
Prior art keywords
substance
methanol
acetone
chloroform
absorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59264579A
Other languages
Japanese (ja)
Other versions
JPS61141889A (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JP59264579A priority Critical patent/JPS61141889A/en
Publication of JPS61141889A publication Critical patent/JPS61141889A/en
Publication of JPH0374677B2 publication Critical patent/JPH0374677B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は、新規な抗生物質SF−2197B物質及
びその製造法に関するものである。更に詳しく述
べれば、新規な抗生物質SF−2197B物質及びミ
クロビスポラ属に属するSF−2197B物質生産菌
を培養し、培養物からSF−2197B物質を採取す
ることよりなる該物質の製造法に関するものであ
る。 本発明者らは、種々のグラム陽性菌及び陰性菌
並びに嫌気性菌に抗菌活性を有する新規、かつ有
用な抗生物質を探索した結果、ミクロビスポラ属
に属する菌株の培養物中に新規抗生物質SF−
2197B物質が生産されていることを見い出し、そ
の有効物質を培養物中から純粋に単離し、その理
化学的性状及び生物学的性状を確定することによ
り、本発明を完成させた。 本発明に使用されるSF−2197B物質生産菌の
一例としては、静岡県焼津市の士壌より分離され
た放線菌SF−2197株がある。SF−2197株の菌学
的性状は下記の通りである。 形態的性質 グルコース・アスパラギン寒天,ベネツト寒
天等で単純分枝の気菌糸をよく着生し、気菌糸
上に多数の互生する短い胞子連鎖を形成する。
電子顕微鏡による観察では、胞子の連鎖は2個
の場合が多いが、3個の連鎖もかなり見うけら
れ、4個の場合もある。胞子の表面はスムー
ス、胞子の形態は長円形〜卵形で大きさは0.4
〜0.6×0.6〜1.2μmである。運動性は認められ
ない。基中菌糸はよく伸長、分枝し分断は見ら
れない。その他胞子のう,菌核,結束糸等の特
殊な構造は観察できなかつた。 各種培地上での生育状態
The present invention relates to a novel antibiotic SF-2197B substance and a method for producing the same. More specifically, the present invention relates to a novel antibiotic SF-2197B substance and a method for producing the substance, which comprises culturing SF-2197B substance-producing bacteria belonging to the genus Microbispora and collecting the SF-2197B substance from the culture. . The present inventors searched for new and useful antibiotics that have antibacterial activity against various Gram-positive and -negative bacteria as well as anaerobic bacteria. As a result, the novel antibiotic SF-
The present invention was completed by discovering that substance 2197B was produced, isolating its effective substance pure from the culture, and determining its physicochemical and biological properties. An example of the SF-2197B substance-producing bacterium used in the present invention is the actinomycete SF-2197 strain isolated from Shiyang, Yaizu City, Shizuoka Prefecture. The mycological properties of SF-2197 strain are as follows. Morphological properties: It adheres well to simply branched aerial hyphae on glucose-asparagine agar, Bennetts agar, etc., and forms numerous short, alternating spore chains on the aerial hyphae.
When observed using an electron microscope, there are often two chains of spores, but chains of three spores are also frequently seen, and there are cases of four. The surface of the spore is smooth, the shape of the spore is oval to oval, and the size is 0.4
~0.6×0.6~1.2 μm. No motility observed. The basal hyphae are well elongated and branched, with no division observed. Other special structures such as sporangia, sclerotia, and binding threads were not observed. Growth status on various media

【表】 SF−2197株の各種培地上での生育状態は、
この表に示した通りである。培養は28℃、観察
は14〜21日培養後に行つた。 生理的性質 (1) 生育温度範囲:イースト麦芽寒天において
15〜42℃の温度範囲に生育し、25〜30℃で良
好に生育する。 (2) ゼラチンの液化:陰性 (3) スターチの加水分解:陰性 (4) 脱脂乳のペプトン化:陰性 脱脂乳の凝固:陰性 (5) 硝酸塩の還元:陰性 (6) 耐塩性:5%食塩では生育するが、7%以
上では生育しない。 (7) メラニン様色素の生成:疑わしい 炭素源の利用性(プリードハム・ゴツトリー
ブ寒天培地) (1) 利用する糖:D−グルコース,D−フラク
トース,D−キシロース,グリセロール,L
−アラビノース,D.マンニトール,ラフイ
ノース,L−ラムノース,シユークロース (2) 利用しない糖:i−イノシトール 細胞壁組成 ベツカー(Becker)らの方法〔Appl.
Microbiol.,12,421(1964)〕及びルシバリエ
(Lechevalier)の方法〔J.Lab.Clin.Med.,71
934(1968)〕により分析した結果、全細胞加水
分解物中のジアミノピメリン酸はDL型であり、
キシロース,アラビノースは検出できなかつ
た。 以上の菌学的性状から、SF−2197株は放線菌
の中でミクロビスポラ(Microbispora)属とミ
クロテトラスポラ(Microtetraspora)属の中間
的菌株と考えられるが、主として胞子連鎖が2個
であることを重視し、ミクロビスポラ属に所属さ
せることにした。 従つて、本発明者らはSF−2197株をミクロビ
スポラ・エスピー・SF−2197(Microbispora sp.
SF−2197)と命名した。なお、本菌株は微工研
に、受託番号第7213号(FERM P−7213)とし
て寄託されている。 SF−2197株は、他の放線菌の菌株の場合にみ
られるように、その性状が変化しやすく、例えば
紫外線,エツクス線,放射線,薬品等を用いる人
工変異手段で変異しうるものであり、いずれの変
異株であつてもSF−2197B物質の生産能を有す
るものはすべて本発明の方法に使用することがで
きる。 本発明の方法では、前記菌株を通常の微生物が
利用しうる栄養物を含有する培地で培養する。栄
養源としては従来より放線菌の培養に利用されて
いる公知のものが使用できる。例えば炭素源とし
てグルコース,グリセロール,シユークロース,
スターチ,水あめ、デキストリン,糖密,オート
ミール,食用油等を使用しうる。また、窒素源と
しては大豆粉,小麦胚芽,綿実かす,トマトケチ
ヤツプ,コーンステイープリカー,肉エキス,ペ
プトン,酵母エキス,硫酸アンモニウム,硝酸ナ
トリウム等を使用しうる。その他必要に応じて炭
酸カルシウム,塩化ナトリウム,塩化コバルト,
リン酸塩,硫酸マグネシウム等の無機塩類を添加
する他、菌の生育を助け、SF−2197B物質の生
産を促進するごとき有機及び無機物質を適当に添
加することができる。 培養法としては、一般抗生物質生産の公知の方
法と同じく、好気的条件下での液体培養法、特に
探部培養法が最も適している。培養に適当な温度
は20℃〜35℃であるが、多くの場合25℃〜30℃の
範囲で培養することが好ましい。 SF−2197B物質の生産は、使用する培地や培
養方法によつても異なるが、振盪培養法あるいは
培養タンクを用いる深部培養法では通常2〜7日
の間でその蓄積が最高に達する。 SF−2197B物質の検定にあたつては次の方法
が用いられる。検定用培地としてはガム寒天培地
(日水製薬)を用いる。検定菌としてはバクテロ
イデス・フラギリス(Bacteroides fragilis)を
用いる。 SF−2197B物質は0.25μg/ml〜1μg/mlにおい
て、濃度の対数と阻止円径との関係は直線関係を
示し、それぞれ16.4mm〜23.3mmの阻止円径を与え
る(ペーパーデイスク平板法)。 本発明により得られるSF−2197B物質は脂溶
性,中性物質である。これを培養物より採取する
に当つて、その抽出,精製にはアンバーライト
XAD−2(ローム・アンド・ハース社製),ダイ
ヤイオンHP−20(三菱化成社製)等の合成吸着
剤,セフアデツクスLH−20,トヨパールHW−
40(東洋ソーダ社製)等のゲル濾過剤,ヘキサン
による沈澱法,酢酸エチル等による溶媒抽出法,
シリカゲルによるカラムクロマトグラフイー等が
有効であるが、以下の方法が効率的である。即
ち、培養液より菌体その他の固型物をケイソウ土
等の濾過助剤を用いて濾別し、次いで、濾液中の
有効成分をダイヤイオンHP−20に吸着させる。
樹脂部を水洗後、50%メタノール水で予洗後、有
効成分を80%アセトン水で溶出する。活性画分を
減圧濃縮し、アセトンを溜去した濃縮液から酢酸
エチルで有効成分を抽出する。この抽出液を減圧
濃縮後、n−ヘキサンを加え有効成分を沈澱させ
る。沈澱物をセフアデツクスLH−20,シリカゲ
ル等のカラムクロマトグラフイー,高速液体クロ
マトグラフイー等を適宜組合わせることにより
SF−2197B物質の純品を得ることができる。 以下にSF−2197B物質の理化学的性状を示す。 (1) 元素分析値:炭素59.22%,水素9.31%,窒
素12.37%,酸素19.1%(差) (2) 分子量:質量分析(SIMS)によりm/z481
に(M++1)のピークが認められることか
ら分子量は480と考えられる。 (3) 融点:78℃ (4) 比旋光度:〔α〕25 p=−20.2゜
(Cl,メタノール) (5) 紫外部吸収スペクトル:特徴的吸収を示さな
い。 (6) 赤外部吸収スペクトル:臭化カリウム錠中で
測定したスペクトルは第1図に示した通りで
あり、下記の吸収ピークを有する。 吸収ピーク(νcm-1):3300,2950,2920,
2850,1720,1660,1620,1540,1440,
1420,1360,1250,1160,1060,990,920,
860 (7) 溶解度:メタノール,クロロホルム,アセト
ン,酢酸エチルに可溶。水,n−ヘキサンに
不溶。 (8) 呈色反応:レミユー,ヨウ素試薬及び塩化第
2鉄試薬陽性。 ニンヒドリン及び硫酸試薬陰性。 (9) 薄層クロマトグラフイーのRf値:シリカゲ
ル60 F254(メルク社製) クロロホルム−メタノール (10:1) 0.51 ベンゼン−アセトン (1:1) 0.42 (10) 中性,酸性,塩基性の区別:中性 (11) 物質の色:白色 (12) 1H−NMRスペクトル:重クロロホルム中
400MHzで測定したスペクトルを第2図に示
す。 (13) 13C−NMRスペクトル:重クロロホルム中
100MHzで測定したスペクトルを第3図に示
した通りであり、下記の吸収ピークを有す
る。 吸収ピーク(ppm):11.65,13.99,16.10,
20.92,22.43,24.28,26.20,26.36,28.53,
31.76,32.71,34.85,36.69,36.90,47.36,
50.27,63.05,169.81,172.20,177.39,
208.13 次に、SF−2197B物質の各種細菌に対する最
小発育阻止濃度(MIC)を第1表に、また各種
嫌気性菌に対する最小発育阻止濃度(MIC)を
第2表に示す。これらの表が示すごとく、SF−
2197B物質は種々のグラム陽性菌及び嫌気性菌に
抗菌活性を有し、これら細菌や嫌気性菌に起因す
るヒト、動物の疾病の予防および治療に用いられ
る。
[Table] Growth status of SF-2197 strain on various media:
As shown in this table. Culture was performed at 28°C, and observation was performed after 14 to 21 days of culture. Physiological properties (1) Growth temperature range: in yeast malt agar
It grows in a temperature range of 15-42°C and grows well at 25-30°C. (2) Liquefaction of gelatin: Negative (3) Hydrolysis of starch: Negative (4) Peptonization of skim milk: Negative Coagulation of skim milk: Negative (5) Reduction of nitrate: Negative (6) Salt tolerance: 5% salt However, it will not grow at 7% or more. (7) Production of melanin-like pigment: doubtful Utilization of carbon source (Pridham-Gottlieb agar medium) (1) Sugars used: D-glucose, D-fructose, D-xylose, glycerol, L
-arabinose, D. mannitol, raffinose, L-rhamnose, sucrose (2) Unutilized sugar: i-inositol Cell wall composition Method of Becker et al. [Appl.
Microbiol., 12 , 421 (1964)] and Lechevalier's method [J.Lab.Clin.Med., 71 ,
934 (1968)], the diaminopimelic acid in the whole cell hydrolyzate was of the DL type;
Xylose and arabinose could not be detected. Based on the above mycological properties, strain SF-2197 is considered to be an intermediate strain between the genera Microbispora and Microtetraspora among actinomycetes, but it is mainly due to the fact that it has two spore chains. We decided to place it in the Microbispora genus. Therefore, the present inventors used the SF-2197 strain as Microbispora sp.
SF-2197). In addition, this strain has been deposited with the FIKEN under accession number 7213 (FERM P-7213). The SF-2197 strain is susceptible to changes in its properties, as seen in the case of other actinomycete strains, and can be mutated by artificial mutagenesis methods using, for example, ultraviolet rays, X-rays, radiation, chemicals, etc. Any mutant strain capable of producing the SF-2197B substance can be used in the method of the present invention. In the method of the present invention, the strain is cultured in a medium containing nutrients that can be utilized by common microorganisms. As the nutrient source, any known nutrient source that has been conventionally used for culturing actinomycetes can be used. For example, glucose, glycerol, sucrose,
Starch, starch syrup, dextrin, molasses, oatmeal, edible oil, etc. can be used. Further, as the nitrogen source, soybean flour, wheat germ, cotton seed cake, tomato ketchup, cornstarch liquor, meat extract, peptone, yeast extract, ammonium sulfate, sodium nitrate, etc. can be used. Other calcium carbonate, sodium chloride, cobalt chloride, as needed.
In addition to adding inorganic salts such as phosphates and magnesium sulfate, organic and inorganic substances that aid the growth of bacteria and promote production of the SF-2197B substance can be added as appropriate. The most suitable culture method is a liquid culture method under aerobic conditions, especially a probe culture method, similar to known methods for producing general antibiotics. The appropriate temperature for culturing is 20°C to 35°C, but in most cases it is preferable to culture at a temperature in the range of 25°C to 30°C. The production of SF-2197B substance varies depending on the medium and culture method used, but in the shaking culture method or the deep culture method using a culture tank, the accumulation usually reaches its maximum within 2 to 7 days. The following method is used for assaying SF-2197B substances. Gum agar medium (Nissui Pharmaceutical Co., Ltd.) is used as the assay medium. Bacteroides fragilis is used as the test bacterium. The SF-2197B substance exhibits a linear relationship between the logarithm of the concentration and the inhibition circle diameter at 0.25 μg/ml to 1 μg/ml, giving inhibition circle diameters of 16.4 mm to 23.3 mm, respectively (paper disk plate method). The SF-2197B substance obtained by the present invention is a fat-soluble, neutral substance. When collecting this from the culture, Amberlite is used for its extraction and purification.
Synthetic adsorbents such as XAD-2 (manufactured by Rohm and Haas), Diaion HP-20 (manufactured by Mitsubishi Kasei), Cephadex LH-20, Toyopearl HW-
40 (manufactured by Toyo Soda Co., Ltd.), precipitation with hexane, solvent extraction with ethyl acetate, etc.
Column chromatography using silica gel is effective, but the following method is more efficient. That is, bacterial cells and other solid substances are filtered out from the culture solution using a filter aid such as diatomaceous earth, and then the active ingredients in the filtrate are adsorbed onto Diaion HP-20.
After washing the resin part with water and pre-washing with 50% methanol water, the active ingredient is eluted with 80% acetone water. The active fraction is concentrated under reduced pressure, and the active ingredient is extracted with ethyl acetate from the concentrated solution after distilling off the acetone. After concentrating this extract under reduced pressure, n-hexane is added to precipitate the active ingredients. The precipitate was chromatographed using an appropriate combination of Sephadex LH-20, column chromatography such as silica gel, high performance liquid chromatography, etc.
Pure SF-2197B substance can be obtained. The physical and chemical properties of SF-2197B substance are shown below. (1) Elemental analysis values: carbon 59.22%, hydrogen 9.31%, nitrogen 12.37%, oxygen 19.1% (difference) (2) Molecular weight: m/z 481 by mass spectrometry (SIMS)
Since a peak of (M + +1) is observed, the molecular weight is thought to be 480. (3) Melting point: 78℃ (4) Specific optical rotation: [α] 25 p = −20.2°
(Cl, methanol) (5) Ultraviolet absorption spectrum: Shows no characteristic absorption. (6) Infrared absorption spectrum: The spectrum measured in the potassium bromide tablet is as shown in Figure 1, and has the following absorption peaks. Absorption peak (νcm -1 ): 3300, 2950, 2920,
2850, 1720, 1660, 1620, 1540, 1440,
1420, 1360, 1250, 1160, 1060, 990, 920,
860 (7) Solubility: Soluble in methanol, chloroform, acetone, and ethyl acetate. Insoluble in water and n-hexane. (8) Color reaction: Remieux, iodine reagent and ferric chloride reagent positive. Ninhydrin and sulfuric acid reagents negative. (9) Rf value of thin layer chromatography: Silica gel 60 F254 (manufactured by Merck & Co.) Chloroform-methanol (10:1) 0.51 Benzene-acetone (1:1) 0.42 (10) Distinction between neutral, acidic, and basic : Neutral (11) Color of substance: White (12) 1 H-NMR spectrum: In deuterochloroform
Figure 2 shows the spectrum measured at 400MHz. (13) 13 C-NMR spectrum: in deuterated chloroform
The spectrum measured at 100MHz is shown in Figure 3, and has the following absorption peaks. Absorption peak (ppm): 11.65, 13.99, 16.10,
20.92, 22.43, 24.28, 26.20, 26.36, 28.53,
31.76, 32.71, 34.85, 36.69, 36.90, 47.36,
50.27, 63.05, 169.81, 172.20, 177.39,
208.13 Next, Table 1 shows the minimum inhibitory concentration (MIC) of SF-2197B substance against various bacteria, and Table 2 shows the minimum inhibitory concentration (MIC) against various anaerobic bacteria. As these tables show, SF−
Substance 2197B has antibacterial activity against various Gram-positive bacteria and anaerobic bacteria, and is used for the prevention and treatment of human and animal diseases caused by these bacteria and anaerobic bacteria.

【表】【table】

【表】 以上述べた諸性状より本発明の化合物に類似す
る既知抗生物質としてSF−2197A物質(特願昭
58−189591)があげられるが、SF−2197A物質
とは質量分析値及びNMRスペクトルより明らか
に区別されることにより、SF−2197B物質を新
規な抗生物質と判定するに至つた。 以下に本発明の実施例を示すが、これらは単な
る一例であつて、本発明を限定するものではな
い。ここに例示しなかつた多くの変法あるいは修
飾手段を用い得ることはもちろんである。 実施例 1 種菌用培地(グルコース.0%,スターチ1.0
%,ペプトン0.5%,イーストエキス0.3%,大豆
粉0.2%,ミートエキス0.2%,炭酸カルシウム0.1
%)を100ml容三角フラスコに20ml分注滅菌後、
ミクロビスポラ・エスピーSF−2197株(FERM
P−7213)をイーストスターチ寒天斜面培養より
3〜4白金耳接種し、28℃で3日間培養した。得
られた種菌50mlを、上記培地1を5容三角フ
ラスコ2本に分注滅菌したものに接種し、28℃で
24時間振盪培養した。 次に、この種菌1を、上記培地35を50容
ジヤーフアーメンター2基に入れ滅菌後接種し、
28℃で24時間培養した。この種培養液30を滅菌
した生産培地(水飴6.0%,大豆油0.3%,サング
レイン(サントリー社製)1.0%,綿実粕1.5%,
グルテンミール1.2%,小麦胚芽0.8%,炭酸カル
シウム0.2%)200を含む300容ステンレスタ
ンク2基に接種し、28℃で4日間通気撹拌培養し
た(通気量200/分,撹拌初期100回転/分,2
日目から150回転/分)。 培養終了後、培養液のPHを2.0に調節し、ケイ
ソウ土を助剤に用いて濾過し培養液280を得た。 実施例 2 実施例1で得られた培養液280をPH7.0に調節
後、ダイヤイオンHP−20(三菱化成社製)15
にバツチ法にて有効成分を吸着させた。樹脂を回
収後、塔につめ30の水で洗浄したのち50%メタ
ノール水60にて予洗を行つた。さらに、80%ア
セトン水にて溶離した。活性区分30を集め、減
圧濃縮し、アセトンを溜去した。濃縮液10に酢
酸エチル10を加え有効物質を抽出した。 この抽出液を減圧下で濃縮し、100mlになつた
ところn−ヘキサン1を加えて放置すると、有
効物質は沈澱した。上澄を除去した後、沈澱物を
メタノールに溶解させ、セフアデツクスLH−20
(フアルマシア社製)700mlの塔に付し、メタノー
ルで展開すると、20ml分画でフラクシヨン24〜36
に有効物質が溶出した。この活性フラクシヨンを
合併し、減圧下で濃縮乾固すると、SF−2197B
物質の粗粉末7.8gが得られた。 この粗粉末をクロロホルムで充填したワコーゲ
ルC−200(和光純薬製)250mlの塔に付し、クロ
ロホルム−メタノール(50:1)混液で展開する
と、15ml分画でフラクシヨン80〜130に有効物質
が溶出した。活性フラクシヨンを合併し、濃縮乾
固すると、SF−2197B物質の粗粉末1.9gが得ら
れた。この1.9gをメタノールで充填したトヨパ
ールHW−40(東洋ソーダ社製)500mlの塔に付し
メタノールにて展開すると、20ml分画でフラクシ
ヨン24〜30に活性フラクシヨンが得られた。この
活性フラクシヨンを合併し減圧下で濃縮乾固する
と、SF−2197B物質の粗粉末880mgが得られた。 実施例 3 実施例2で得られたSF−2197B物質の粗粉末
300mgを1mlのメタノールに溶解し、YMC−
PACK S−343(ODS)(山村化学社製)のカラ
ム(20φ×250mm)を用いた高速液体クロマトグ
ラフイーで4ml/分の流速にて70%メタノールで
展開し、活性画分を濃縮乾固し、80mgの粗粉末を
得た。 さらに、この粗粉末をアセトニトリルで充填し
たLH−20 200mlの塔に付し、アセトニトリルに
て展開し、活性画分を減圧下で濃縮乾固してSF
−2197B物質の白色粉末17mgを得た。本物質は前
記の理化学的性質を有する。
[Table] Based on the properties described above, SF-2197A substance (patent application) is a known antibiotic similar to the compound of the present invention.
58-189591), but as it was clearly distinguished from the SF-2197A substance based on mass spectrometry values and NMR spectra, the SF-2197B substance was determined to be a new antibiotic. Examples of the present invention are shown below, but these are merely examples and do not limit the present invention. Of course, many variations or modifications not exemplified here may be used. Example 1 Inoculum culture medium (glucose 0%, starch 1.0%)
%, peptone 0.5%, yeast extract 0.3%, soy flour 0.2%, meat extract 0.2%, calcium carbonate 0.1
%) into a 100ml Erlenmeyer flask.After sterilization,
Microbispora sp. SF-2197 strain (FERM
P-7213) was inoculated in 3 to 4 platinum loops from yeast starch agar slant culture and cultured at 28°C for 3 days. 50 ml of the obtained inoculum was inoculated into two sterilized 5-volume Erlenmeyer flasks containing the above medium 1, and incubated at 28°C.
It was cultured with shaking for 24 hours. Next, this inoculum 1 was sterilized by putting the above medium 35 into two 50-volume jar fermenters, and then inoculating it.
Cultured at 28°C for 24 hours. Production medium sterilized with this seed culture solution 30 (6.0% starch syrup, 0.3% soybean oil, 1.0% Sungrain (manufactured by Suntory), 1.5% cottonseed meal,
Gluten meal 1.2%, wheat germ 0.8%, calcium carbonate 0.2%) were inoculated into two 300 volume stainless steel tanks and cultured at 28℃ for 4 days with aeration and stirring (aeration rate 200/min, initial stirring 100 revolutions/min). ,2
150 revolutions/minute from day one). After the cultivation was completed, the pH of the culture solution was adjusted to 2.0, and the culture solution was filtered using diatomaceous earth as an aid to obtain culture solution 280. Example 2 After adjusting the culture solution 280 obtained in Example 1 to pH 7.0, Diaion HP-20 (manufactured by Mitsubishi Kasei Corporation) 15
The active ingredients were adsorbed using the batch method. After collecting the resin, it was washed with 30 ml of water in a tower, and then pre-washed with 60 ml of 50% methanol water. Further, elution was performed with 80% acetone water. The active fraction 30 was collected and concentrated under reduced pressure to distill off acetone. Ethyl acetate (10%) was added to 10% of the concentrated solution to extract the effective substance. This extract was concentrated under reduced pressure to a volume of 100 ml, after which one portion of n-hexane was added and allowed to stand, causing the effective substance to precipitate. After removing the supernatant, the precipitate was dissolved in methanol and added to Cephadex LH-20.
(Manufactured by Pharmacia) When attached to a 700ml column and developed with methanol, fractions 24 to 36 were obtained in 20ml fractions.
The active substance was eluted. The active fractions were combined and concentrated to dryness under reduced pressure to form SF-2197B.
7.8 g of coarse powder of material was obtained. This crude powder was applied to a 250 ml column of Wako Gel C-200 (manufactured by Wako Pure Chemical Industries, Ltd.) filled with chloroform and developed with a chloroform-methanol (50:1) mixture. It eluted. The active fractions were combined and concentrated to dryness to yield 1.9 g of a crude powder of SF-2197B material. When this 1.9 g was applied to a 500 ml column of Toyopearl HW-40 (manufactured by Toyo Soda Co., Ltd.) filled with methanol and developed with methanol, active fractions 24 to 30 were obtained in 20 ml fractions. The active fractions were combined and concentrated to dryness under reduced pressure to obtain 880 mg of a crude powder of SF-2197B substance. Example 3 Coarse powder of SF-2197B substance obtained in Example 2
Dissolve 300mg in 1ml of methanol and add YMC-
Using high performance liquid chromatography using a PACK S-343 (ODS) (manufactured by Yamamura Chemical Co., Ltd.) column (20φ x 250 mm), the active fraction was developed with 70% methanol at a flow rate of 4 ml/min, and the active fraction was concentrated to dryness. 80 mg of coarse powder was obtained. Furthermore, this crude powder was applied to an LH-20 200 ml column filled with acetonitrile, developed with acetonitrile, and the active fraction was concentrated to dryness under reduced pressure to obtain SF.
17 mg of white powder of -2197B substance was obtained. This substance has the above-mentioned physicochemical properties.

【図面の簡単な説明】[Brief explanation of drawings]

第1図はSF−2197B物質の臭化カリウム錠中
での赤外部吸収スペクトルである。第2図はSF
−2197B物質の重クロロホルム溶液中での 1H−
NMRスペクトルである。第3図はSF−2197B物
質の重クロロホルム溶液中での 13C−NMRスペ
クトルである。
Figure 1 shows the infrared absorption spectrum of SF-2197B substance in potassium bromide tablets. Figure 2 is SF
−2197B substance in deuterated chloroform solution 1 H−
This is an NMR spectrum. Figure 3 is a 13 C-NMR spectrum of SF-2197B substance in deuterated chloroform solution.

Claims (1)

【特許請求の範囲】 1 下記の理化学的性質を有するSF−2197B物
質。 1) 元素分析値:炭素59.22%,水素9.31%,
窒素12.37%,酸素19.1% 2) 分子量:質量分析(SIMS)によりm/
z481に(M++1)のピークが認められるこ
とから分子量は480と考えられる。 3) 融点:78℃ 4) 比旋光度:〔α〕25 p=−20.2゜ 5) 紫外部吸収スペクトル:特徴的吸収を示さ
ない。 6) 赤外部吸収スペクトル:下記の吸収ピーク
(νcm-1)を有する。 3300,2950,2920,2850,1720,1660,
1620,1540,1440,1420,1360,1250,
1160,1060,990,920,860 7) 溶解度:メタノール,クロロホルム,アセ
トン,酢酸エチルに可溶。水,n−ヘキサン
に不溶。 8) 呈色反応:レミユー,ヨウ素試薬及び塩化
第2鉄試薬陽性。 9) 薄層クロマトグラフイーのRf値:シリカ
ゲル60F254(メルク社製) クロロホルム−メタノール (10:1) 0.51 ベンゼン−アセトン (1:1) 0.42 10) 中性,酸性,塩基性の区別:中性 11) 物質の色:白色 12) 13C−NMRスペクトル:下記の吸収ピー
ク(ppm)を有する。 11.65,13.99,16.10,20.92,22.43,24.28,
26.20,26.36,28.53,31.76,32.71,34,85,
36.69,36.90,47.36,50.27,63.05,169.81,
172.20,177.39,208.13 2 ミクロビスポラ属に属する抗生物質SF−
2197B生産菌を培地に培養し、培養物から下記の
理化学的性質を有するSF−2197B物質を単離す
ることを特徴とする新抗生物質SF−2197B物質
の製造法。 1) 元素分析値:炭素59.22%,水素9.31%,
窒素12.37%,酸素19.1% 2) 分子量:質量分析(SIMS)によりm/
z481に(M++1)のピークが認められるこ
とから分子量は480と考えられる。 3) 融点:78℃ 4) 比旋光度:〔α〕25 p=−20.2゜ 5) 紫外部吸収スペクトル:特徴的吸収を示さ
ない。 6) 赤外部吸収スペクトル:下記の吸収ピーク
(νcm-1)を有する。 3300,2950,2920,2850,1720,1660,
1620,1540,1440,1420,1360,1250,
1160,1060,990,920,860 7) 溶解度:メタノール,クロロホルム,アセ
トン,酢酸エチルに可溶。水,n−ヘキサン
に不溶。 8) 呈色反応:レミユー,ヨウ素試薬及び塩化
第2鉄試薬陽性。 9) 薄層クロマトグラフイーのRf値:シリカ
ゲル60 F254(メルク社製) クロロホルム−メタノール (10:1) 0.51 ベンゼン−アセトン (1:1) 0.42 10) 中性,酸性,塩基性の区別:中性 11) 物質の色:白色 12) 13C−NMRスペクトル:下記の吸収ピー
ク(ppm)を有する。 11.65,13.99,16.10,20.92,22.43,24.28,
26.20,26.36,28.53,31.76,32.71,34.85,
36.69,36.90,47.36,50.27,63.05,169.81,
172.20,177.39,208.13
[Claims] 1. SF-2197B substance having the following physical and chemical properties. 1) Elemental analysis values: carbon 59.22%, hydrogen 9.31%,
12.37% nitrogen, 19.1% oxygen 2) Molecular weight: m/m by mass spectrometry (SIMS)
The molecular weight is thought to be 480 because a peak of (M + +1) is observed at z481. 3) Melting point: 78°C 4) Specific optical rotation: [α] 25 p = -20.2° 5) Ultraviolet absorption spectrum: No characteristic absorption is shown. 6) Infrared absorption spectrum: It has the following absorption peak (νcm -1 ). 3300, 2950, 2920, 2850, 1720, 1660,
1620, 1540, 1440, 1420, 1360, 1250,
1160, 1060, 990, 920, 860 7) Solubility: Soluble in methanol, chloroform, acetone, and ethyl acetate. Insoluble in water and n-hexane. 8) Color reaction: Remieux, iodine reagent and ferric chloride reagent positive. 9) Rf value of thin layer chromatography: Silica gel 60F254 (manufactured by Merck) Chloroform-methanol (10:1) 0.51 Benzene-acetone (1:1) 0.42 10) Distinction between neutral, acidic, and basic: Neutral 11) Color of substance: White 12) 13 C-NMR spectrum: It has the following absorption peaks (ppm). 11.65, 13.99, 16.10, 20.92, 22.43, 24.28,
26.20, 26.36, 28.53, 31.76, 32.71, 34, 85,
36.69, 36.90, 47.36, 50.27, 63.05, 169.81,
172.20, 177.39, 208.13 2 SF-, an antibiotic belonging to the genus Microbispora
A method for producing a new antibiotic SF-2197B substance, which comprises culturing 2197B-producing bacteria in a medium and isolating an SF-2197B substance having the following physicochemical properties from the culture. 1) Elemental analysis values: carbon 59.22%, hydrogen 9.31%,
12.37% nitrogen, 19.1% oxygen 2) Molecular weight: m/m by mass spectrometry (SIMS)
The molecular weight is thought to be 480 because a peak of (M + +1) is observed at z481. 3) Melting point: 78°C 4) Specific optical rotation: [α] 25 p = -20.2° 5) Ultraviolet absorption spectrum: No characteristic absorption is shown. 6) Infrared absorption spectrum: It has the following absorption peak (νcm -1 ). 3300, 2950, 2920, 2850, 1720, 1660,
1620, 1540, 1440, 1420, 1360, 1250,
1160, 1060, 990, 920, 860 7) Solubility: Soluble in methanol, chloroform, acetone, and ethyl acetate. Insoluble in water and n-hexane. 8) Color reaction: Remieux, iodine reagent and ferric chloride reagent positive. 9) Rf value of thin layer chromatography: Silica gel 60 F254 (manufactured by Merck) Chloroform-methanol (10:1) 0.51 Benzene-acetone (1:1) 0.42 10) Distinction between neutral, acidic, and basic: Medium 11) Color of substance: White 12) 13 C-NMR spectrum: It has the following absorption peaks (ppm). 11.65, 13.99, 16.10, 20.92, 22.43, 24.28,
26.20, 26.36, 28.53, 31.76, 32.71, 34.85,
36.69, 36.90, 47.36, 50.27, 63.05, 169.81,
172.20, 177.39, 208.13
JP59264579A 1984-12-17 1984-12-17 Novel antibiotic sf-2197b and its preparation Granted JPS61141889A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP59264579A JPS61141889A (en) 1984-12-17 1984-12-17 Novel antibiotic sf-2197b and its preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59264579A JPS61141889A (en) 1984-12-17 1984-12-17 Novel antibiotic sf-2197b and its preparation

Publications (2)

Publication Number Publication Date
JPS61141889A JPS61141889A (en) 1986-06-28
JPH0374677B2 true JPH0374677B2 (en) 1991-11-27

Family

ID=17405245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59264579A Granted JPS61141889A (en) 1984-12-17 1984-12-17 Novel antibiotic sf-2197b and its preparation

Country Status (1)

Country Link
JP (1) JPS61141889A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005104552A1 (en) 2004-04-23 2005-11-03 Sumitomo Electric Industries, Ltd. Moving picture data encoding method, decoding method, terminal device for executing them, and bi-directional interactive system

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02146397A (en) * 1988-11-26 1990-06-05 Shiro Kanao Pressure-proof spiral corrugated pipe
JPH02179213A (en) * 1988-12-27 1990-07-12 Shiro Kanao Pressure-proof spiral corrugated pipe
JP3118579B2 (en) * 1992-12-09 2000-12-18 金尾 茂樹 Pressure-resistant synthetic resin tube

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005104552A1 (en) 2004-04-23 2005-11-03 Sumitomo Electric Industries, Ltd. Moving picture data encoding method, decoding method, terminal device for executing them, and bi-directional interactive system

Also Published As

Publication number Publication date
JPS61141889A (en) 1986-06-28

Similar Documents

Publication Publication Date Title
JPS6254433B2 (en)
JPH0374677B2 (en)
US4550021A (en) Antitumor antibiotic 81-484 and process for its production
US5219736A (en) Process for producing 3-deacylated derivative of 16-membered macrolide antibiotic
EP0478064B1 (en) Microbial preparation of 13beta-13-deoxy-22,23-dihydro avermectin-B1a/B1b aglycone
EP0413967B1 (en) Novel antibiotic
JPH06234784A (en) New antibiotic sf 2768 substance and its production
EP0542234B1 (en) Antibacterial substance BE-24566B
JP3117294B2 (en) New antibiotics and their production
JPH0740950B2 (en) Microbial production of nicotianamine
JPH0625095B2 (en) Antibiotic SF-2415 substance and its production method
JPH0254074B2 (en)
JP3380595B2 (en) Novel antibiotics SF2741A and SF2741B and their production
GB2042502A (en) Antibiotics c-14482 b1,b2 and b3
JP2844214B2 (en) Method for producing 4a-hydroxymilbemycin αs
KR0122427B1 (en) Aminopeptidase m inhibitor, process for the preparation thereof and microorganism producing the same
JP3063804B2 (en) Novel macrolide antibiotic SF2748 substance and method for producing the same
JPS6250473B2 (en)
JPS6246550B2 (en)
JPH0656875A (en) New macrolide antibiotic substance sf2757 and its production
JPS6246551B2 (en)
JPH05207884A (en) New macrolide antibiotic substances sf2748b, sf2748c1, sf2748d and sf2748e and their production
JPH0377857A (en) New physiologically active substance dioctatin and its production
JPH0374678B2 (en)
JPH05380B2 (en)